JP5431157B2 - Composition for preventing UV injury for ingestion - Google Patents

Description

  The present invention relates to an ultraviolet injury prevention composition for oral consumption, and more particularly to an ultraviolet injury prevention composition for oral consumption obtained from a composition obtained from a specific plant.

  When skin is exposed to ultraviolet rays, various injuries such as erythema and edema occur, which may cause photoaging and skin cancer such as thickening and loss of elasticity, wrinkles, and abnormal pigmentation. ing. As a means for preventing injury due to ultraviolet rays, it has been common to apply a skin external preparation that blocks ultraviolet rays to the skin.

  However, applying a topical skin preparation to exposed parts of the body is time consuming and time consuming, and since the effect disappears when it is exposed to sweat or water, a simpler and more effective means for preventing ultraviolet rays has been desired. .

  Therefore, studies have been made on pharmacological components that have an effect of protecting the skin from ultraviolet rays by ingestion for the purpose of reducing skin damage caused by ultraviolet rays. For example, it is known that oral intake of carotenoids and vitamin E suppresses skin inflammation (erythema) caused by ultraviolet rays.

  Patent Document 1 describes an oral melanin production-suppressing composition containing a rose or chrysanthemum extract as an active ingredient. Patent Document 2 describes an oral whitening agent containing an extract such as silymarin. Patent Document 3 describes a composition for oral administration containing a rosemary extract, a sage extract and the like, and a whitening agent and a food and drink containing the composition. Patent Document 4 describes an oral whitening agent containing dihydroeudesmol or a glycoside thereof. Patent Document 5 describes an oral administration composition containing cryptoxanthin and cysteine and a whitening agent containing the composition as an active ingredient. Patent Document 6 describes a UV injury preventive agent containing an aqueous solution obtained from olive fruit. Patent Document 7 describes a whitening composition containing a germinated broccoli-derived component and capable of being taken orally.

  However, there have been few studies on compositions for preventing UV injury for oral consumption containing melon extract.

  On the other hand, external preparations and skin cosmetics containing a melon extract are known (Patent Document 8 and Patent Document 9). However, as described above, it is troublesome to apply an external preparation, and in addition to the problem that the effect is lost due to perspiration, etc., these containing a general simple melon extract are used for external preparations and skin cosmetics. The fee was not enough.

  Among the melons, there is a known variety of melons with the varieties of Kukamis and Melo that do not change on the fruit surface even if left for a long period of time. A “soluble protein extract having a preventive ability” is known (Patent Document 10). However, this document relates to a basic examination that the extract has a superoxide dismutase enzyme activity, and the ability to prevent UV damage for oral intake has not been studied at all.

  In addition, a skin cosmetic (skin care composition) containing an extract from the fruit of this Kukamis-Mello variety is known (Patent Document 11). However, although this is effective to some extent as an external preparation or a skin cosmetic, it is not intended for oral consumption, but it contains an extract from the fruit of a variety of Cucamis melo varieties, and it is an ultraviolet radiation injury prevention composition for oral consumption. The thing was not examined at all.

  In addition, when humans that were orally ingested an extract from the fruit of a variety of Cucamis melo varieties were exposed to 2.5 atmospheres of pure oxygen inhalation for 1 hour, leukocytes were compared to humans that were not orally ingested. Although there is a research result that DNA damage is suppressed (Non-Patent Document 1), there has been no study on prevention of ultraviolet ray injury.

  Therefore, there has been a demand for a composition that is excellent in the effect of preventing damage caused by ultraviolet rays when taken orally.

JP 2001-048801 A JP 2002-220333 A JP 2005-112817 A JP 2005-306817 A JP 2006-104088 A JP 2006-219433 A JP 2007-031297 A JP 2003-095858 A JP 2005-532375 A Japanese Patent Laid-Open No. 8-048699 Special table 2007-505034 gazette Free Radical Research, 38 (9), pp.927-932 (2004)

  The present invention has been made in view of the above-described background art, and the problem is that “a composition for oral consumption” effectively prevents and / or suppresses injury caused by exposure of the skin to ultraviolet rays. Is to provide. Another object of the present invention is to provide an “oral intake composition” that can reduce the redness of the skin before the occurrence of erythema (redness) due to ultraviolet rays and has a whitening effect.

  As a result of intensive studies to solve the above-mentioned problems, the inventor of the present invention contains a composition obtained from a specific part of a specific variety of a specific plant, so that it is extremely effective for UV damage by ingestion. As a result, the present invention has been completed.

  That is, the present invention provides a composition for preventing UV injury for oral consumption, which comprises a component obtained from the fruit of a variety of Cucumis melo.

  The present invention also provides an oral preparation characterized by coating the above-mentioned composition for preventing UV injury for oral intake with an enteric coating agent.

  The present invention also provides a skin care product for ingestion characterized by containing the above-mentioned oral preparation. Moreover, this invention provides the food-drinks characterized by containing said oral preparation.

  ADVANTAGE OF THE INVENTION According to this invention, the composition which has the outstanding ultraviolet-ray injury inhibitory effect and ultraviolet-ray injury prevention effect by oral ingestion can be provided. Moreover, the redness of the skin before erythema (redness) generation | occurrence | production by ultraviolet irradiation can be made low, ie, the "composition for ingestion" with a whitening effect can be provided.

The ultraviolet irradiation site | part in Example 1 and Comparative Example 1 is illustrated. The erythma value by the megsometer of Example 1 and Comparative Example 1 is shown (No. 1 to 7 of Evaluation 2). (Square) indicates the result of Example 1, and ◆ (diamond) indicates the result of Comparative Example 1. The data shown in FIG. 2 is obtained by converting the vertical axis into a Δ elliptic value. The analysis method regarding erythema (redness) and melamine deposition is illustrated. The results of all the subjects (the vertical axis is the Δ erythma value) are averaged using the analysis method shown in FIG. It is a graph which shows the relationship between irradiation ultraviolet-ray amount and an erythema value about generation | occurrence | production of erythema (redness) (No. 8 and No. 9 of evaluation 4). (Square) indicates the result of Example 4, and ◆ (diamond) indicates the result of Comparative Example 5. It is a graph which shows the relationship between an irradiation ultraviolet-ray amount and an erythema value about generation | occurrence | production of erythema (redness) (No. 10 of evaluation 4 and No. 11). (Square) indicates the result of Example 4, and ◆ (diamond) indicates the result of Comparative Example 5.

  Hereinafter, the present invention will be described, but the present invention is not limited to the following embodiments, and includes any modifications within the technical scope of the present invention.

<Ingredients obtained from the fruit of Kukamisu Melo variety>
[Specific melon]
The composition for preventing UV injury for oral consumption according to the present invention contains a composition obtained from the fruit of a specific variant of one melon of “Cucamis Melo” (hereinafter abbreviated as “specific melon”). To do. The variant of Cucumis melo in the present invention refers to that described in International Publication Pamphlet WO92 / 02622, the owner of which is the applicant. In addition, seeds were deposited in the NCIMB collection (National Collection of Industrial and Marine Bacteria-ABERDEEN AB2 IRY (Scotland-GB) 23 St. Machar Drive) as No. 40310 on July 19, 1990 in accordance with the Budapest Agreement. A variant of the Vauclusien, Clipper or Supporter type obtained from the melon strain 95LS444 and obtained by hybridization.

  Particularly preferred as a variant of Cucumis melo in the present invention is 95LS444 cell line, hybrid strain derived from 95LS444 cell line, and the like.

  The specific melon is a melon variant obtained by gene crossing and has a storage period (10 to 14 days or more) longer than the conventional type of storage period of about 5 days. That is, the specific melon does not wrinkle on the surface of the melon even after 12 days at room temperature and normal pressure. Ordinary melons that are not specific melons are not suitable for the present invention because wrinkles and the like change on the surface in about 5 days after standing at room temperature and pressure.

  As described in WO 92/02622, it has been clarified that the tissue structure of certain melons is not destroyed by maturation. That is, none of cell destruction, glazing, liquefaction, etc. characteristic of senescent cells of melon has been observed.

  Citrus fruits, grapes, grapes, etc. are said to be non-climacteric fruits, while apples, pears, tomatoes, melons, bananas, etc. are said to be climacteric fruits, but climacteric fruits are mature. Ethylene is released at the starting point. The specific melon is preferably one having a period during which ethylene is steadily released for at least 5 days, preferably at least 7 days after ethylene crisis.

  A person skilled in the art can clearly identify what the “specific melon” in the present invention is referring to WO 92/02622 and the above description.

  The specific melon is preferably a melon in which the enzyme activity (for example, superoxide dismutase (SOD) activity or catalase activity) of the soluble protein extract therefrom is twice or more that of a normal melon. Specifically, the superoxide dismutase (SOD) activity of the water-soluble fraction of the pulp is 10 units / (mg water-soluble fraction) or more, and the catalase activity is 1 units / (mg water-soluble fraction) or more, Melon having a glutathione activity of 500 μg / (100 mg water-soluble fraction) or more. More preferably, the soluble protein extract has a superoxide dismutase (SOD) activity of 50 units / (mg protein) or more and a catalase activity of 60 units / (mg protein) or more. The soluble protein extract and its enzyme activity are described in Patent Document 10.

[Ingredients in specific melon]
The component contained in the composition for preventing UV injury for oral intake of the present invention can be obtained from the specific melon by any method. For example, there is a method of pulverizing or pressurizing the pulp of a specific melon and collecting the supernatant. In order to obtain an extraction component from specific melon efficiently, a method of recovering in an aqueous solvent is preferable. The pH of the aqueous solution at that time is not particularly limited, but is preferably pH 5 to pH 9, and more preferably pH 7 to pH 8. If the pH is too high or too low, the enzyme contained in the specific melon may be denatured to lower the enzyme activity, and the effects of the present invention may not be exhibited.

The water-soluble solvent for recovery is not particularly limited and can be arbitrarily selected as long as it is water-soluble. Specifically, for example,
Water such as deionized water;
Hydrocarbons such as hexane, heptane, liquid paraffin;
Lower alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol;
1.3 Polyhydric alcohol that is liquid at room temperature, such as 3-butylene glycol, propylene glycol, glycerin;
Ethers such as diethyl ether, tetrahydrofuran and dipropyl ether:
Ketones such as acetone and methyl ethyl ketone;
Esters such as ethyl acetate and butyl acetate;
Acetonitrile and the like.

  Since proteins and the like are included, water is preferable, and deionized water is particularly preferable. These water-soluble solvents may be used alone or in combination of two or more.

  At present, as the components extracted from the specific melon by the above method, the substances listed in Table 1 of the examples have been found, but the substances having the effects of the present invention are not limited to these, and there are others. Is expected. Therefore, although it is essential to contain the component obtained from a specific melon in the composition for preventing UV injury for oral intake of the present invention, the specific components are not limited to the substances listed in Table 1.

  The component obtained from the specific melon recovered in the water-soluble solvent may be subjected to concentration, solvent replacement, solvent distillation, etc. so that subsequent processing is easy. Ingredients obtained from specific melons are dissolved in the water-soluble extraction solvent, concentrated, solvent-replaced, evaporated solvent paste, evaporated solvent particles, etc. It is contained in the injury preventing composition.

  In the case of a particle state, it is mechanically stirred as it is and contained in the composition for preventing UV injury for oral intake. Moreover, when it contains in the ultraviolet injury prevention composition for oral intake in a particle | grain state, the volume average particle diameter does not have limitation in particular, However, 50 micrometers-500 micrometers are preferable, and 150 micrometers-200 micrometers are especially preferable.

  The component obtained from the specific melon is preferably protected with an enteric compound (including an enteric solvent and an enteric coating agent) as described later, but when the component obtained from the specific melon is in a particle state, It is also preferred to include only such ingredients with enteric solvents. Examples of the intestinal solvent used for the inclusion of only the components obtained from the specific melon include those described below, but palm oils and fats are preferred in terms of resistance to gastric acid and stabilizing enzyme proteins.

  The component obtained from the specific melon effectively prevents and / or suppresses damage induced by ultraviolet irradiation of the skin by ingestion. In addition, the redness of the skin before the occurrence of erythema (redness) due to ultraviolet rays can be lowered, that is, it has a whitening effect by oral intake.

  In addition to the component obtained from the specific melon, the composition for preventing ultraviolet injury for oral intake of the present invention preferably further contains a polyphenol component in order to synergistically exert the effects of the present invention. The “polyphenol component” is not particularly limited, but the following “red wine component” and / or “component obtained from pine bark” can provide the above effect of the present invention more remarkably and synergistically. Is particularly preferred.

<Red wine ingredient>
In addition to the components obtained from the above-mentioned specific melon, the composition for preventing ultraviolet injury for oral intake of the present invention is further “a polyphenol component contained in red wine obtained by fermenting grape flesh, pericarp or seed” (hereinafter referred to as “polyphenol component”). And abbreviated as “red wine component”) in order to synergistically exhibit the effects of the present invention.

  The “red wine component” suitably contained in the composition for preventing UV injury for oral consumption of the present invention is not particularly limited as long as it is a polyphenol component contained in red wine obtained by fermenting grape flesh, pericarp or seeds. Specifically, for example, phenolic components such as catechins, flavan derivatives such as anthocyanins, flavanols and flavonols, or “all components contained in red wine obtained by fermenting grape pulp, pericarp or seed” Is mentioned. Moreover, these components may contain 1 type, or 2 or more types.

  The shape of the “red wine component” in the present invention is not particularly limited, but powders and fine granules are preferred from the viewpoint of processability and easy handling.

<Ingredients obtained from pine bark>
In addition to the component obtained from the specific melon, the composition for preventing UV injury for oral intake according to the present invention further contains “the component obtained from pine bark” to exhibit the effect of the present invention synergistically. This is preferable.

  The method for obtaining such components from pine bark is not particularly limited. For example, a method for collecting oil-containing resin components by hitting a pine tree, a method for removing oil-containing resin components by peeling pine bark, and damaging the trunk. Examples thereof include a method for recovering the oil-containing resin component. Further, from these, steam distillation, solvent extraction, hot water extraction and the like can also be obtained.

  Particularly preferably, the component is taken out by hot water extraction. That is, the composition for preventing UV injury for oral intake of the present invention contains, in addition to the component obtained from the specific melon, the “component obtained by hot water extraction of pine bark”. This is preferable for synergistically exhibiting the effects of the invention.

  Such components are first extracted with hot water from pine bark, distilled off if necessary, and then extracted with a solvent if necessary. Further, a purification step may be further added. Moreover, it is preferable that it is finally dried to be a solid.

  There are no particular limitations on the type, location, size, and the like of the pine for obtaining the pine bark, and it can be arbitrarily selected. The preferred genus of the pine tree is the French caliper (P. pinaster), more preferably it grows in the southern part of France, particularly preferably the French caliper (P. pinaster) that grows in the land region in the southern part of France. is there. The height of the pine tree is preferably 8 m or more and 30 m or less, and particularly preferably 10 m or more and 25 m or less. The diameter of the pine tree is preferably 50 cm or more and 100 cm or less. In the case of a pine that satisfies the above requirements, the effect of the present invention is more exhibited.

[Hydroxyflavan or derivative thereof or oligomer thereof]
Although the specific compound of the said component obtained from a pine bark does not have limitation in particular, It is preferable that it is a hydroxy flavan or its derivative (s), or those oligomers. Moreover, the unknown component contained in the said pine bark is also preferable.

  Although it does not specifically limit as hydroxyflavan, Flavan-3-ol (3-hydroxyflavan), flavan-3,4-diol (3,4-hydroxyflavan), flavan-3,5,7-triol (3,3) 5,7-hydroxyflavan), flavan-3,4,5,7-tetraol (3,4,5,7-hydroxyflavan), flavan-3,5,7,3 ′, 4′-pentaol ( 3,5,7,3 ', 4'-hydroxyflavan) or derivatives thereof. Moreover, oligomers, such as those dimers, trimers, and tetramers, etc. are mentioned.

［式中、ｎは０〜６の整数を示す。ｎは好ましくは０〜２である。］Specifically, what is represented by a following formula is mentioned, for example.

[In formula, n shows the integer of 0-6. n is preferably 0-2. ]

  Specific names of “hydroxyflavan or derivatives thereof or oligomers thereof” extracted from pine bark in the present invention include, for example, catechin, epicatechin, gallic acid, anthocyanidins, anthocyanins or derivatives thereof, dimers and trimers thereof. And oligomers such as tetramers. These components may be used alone or in combination of two or more.

  The shape of the “component obtained from pine bark” or “hydroxyflavan or a derivative thereof or an oligomer thereof” in the present invention is not particularly limited, but is preferably a powder in terms of processability and availability. Specifically, those having a volume average particle diameter of 50 μm to 500 μm are preferable, and those having a volume average particle diameter of 50 μm to 200 μm are particularly preferable.

<Vitamin C>
In addition to the component obtained from the specific melon, the composition for preventing UV injury for oral intake of the present invention preferably further contains vitamin C in order to synergistically exert the effects of the present invention.

  The vitamin C contained in the composition for preventing UV injury for oral intake of the present invention is not particularly limited, and generally available vitamin C can be used. Specifically, for example, ascorbic acid; ascorbic acid alkali metal salts such as sodium ascorbate and potassium ascorbate: alkaline earth metal salts of ascorbic acid such as calcium ascorbate and magnesium ascorbate. Among them, ascorbic acid, sodium ascorbate, and calcium ascorbate are preferable, and ascorbic acid is more preferable.

  The shape of vitamin C in the present invention is not particularly limited, but a powder is preferable in terms of processability and easy handling.

<Combination of ingredients>
In addition to the above-mentioned “component obtained from the specific melon”, the composition for preventing UV injury for ingestion of the present invention includes “red wine component”, “hydroxyflavan or a derivative thereof or oligomer thereof” such as “from pine bark. The obtained component ”” and / or “vitamin C” is contained as an essential component. There is no particular limitation on the combination with the “component obtained from the specific melon”, and any combination can be used.
"Ingredients obtained from specific melons" and "Red wine ingredients",
"Ingredients obtained from specific melon" and "Ingredients obtained from pine bark",
It is a combination of “component obtained from specific melon” and “red wine component” and “component obtained from pine bark”.
More preferably, it is a combination of “component obtained from specific melon”, “red wine component”, “component obtained from pine bark” and “vitamin C”.

The preferred content of each component in the composition for preventing UV injury for oral intake is, in terms of solid content,
Components obtained from the specific melon 1 part by mass to 100 parts by mass Red wine ingredient 0 parts by mass to 300 parts by mass Components obtained from the pine bark 0 parts by mass to 180 parts by mass The vitamin C 0 parts by mass to 200 parts by mass More preferable content is in terms of solid content,
Ingredients obtained from the specific melon 1 part by mass to 50 parts by mass The red wine ingredient 5 parts by mass to 300 parts by mass Ingredients obtained from the pine bark 5 parts by mass to 180 parts by mass The vitamin C 0 parts by mass to 200 parts by mass Particularly preferred content is in terms of solid content,
Ingredients obtained from the specific melon 2 parts by mass to 20 parts by mass The red wine ingredient 10 parts by mass to 200 parts by mass Ingredients obtained from the pine bark 10 parts by mass to 120 parts by mass The vitamin C 1 part by mass to 200 parts by mass It is.

  When the component obtained from the specific melon is too small, the effect of the present invention may not be obtained. When the red wine component is too small, the effect of the present invention may not be obtained. In addition, when there are too few components obtained from the pine bark, the effect of the present invention may not be obtained, while when there are too many components obtained from the specific melon, It may be excreted without expressing activity in the body.

<Enteric compound>
In the present invention, it is preferable to use an enteric compound in order to obtain the effect of the present invention. The enteric compound in the present invention is an enteric substance that dissolves after entering the small intestine instead of the stomach in order to further increase the enzyme activity in the intestine. The enteric compound in the present invention is preferably one that decomposes or dissolves at pH 7.5 or higher. Further, the “enteric compound” in the present invention refers to both the following enteric solvents and enteric coating agents.

(Enteric solvent)
In the present invention, a compound that is included to protect the “component obtained from a specific melon” from gastric juice is referred to as an intestinal solvent. The ultraviolet ray injury preventing composition for oral intake of the present invention may be taken orally as it is, but in order to further enhance the enzyme activity in the intestine and to dissolve after entering the small intestine instead of the stomach, Inclusion is preferred to protect with a solvent. Among the components obtained from the above specific melon, the enzyme component is a protein, so it is easily decomposed by gastric acid and easily decomposed before the enzyme activity is expressed. There is an effect that the composition for preventing injury can reach the intestines.

  The content of the enteric solvent can be appropriately adjusted depending on the type of enteric solvent, but is preferably 100 parts by mass to 5000 parts by mass with respect to 100 parts by mass of the “component obtained from the specific melon”, and 100 parts by mass. -1000 mass parts is more preferable, and 200 mass parts-500 mass parts is especially preferable. If too much enteric solvent is present, the specific activity, which is the enzyme activity per part by mass, may be reduced, resulting in an excessive intake. Since the protein component of the prevention composition is considered to be degraded in the stomach, the activity of the enzyme is deactivated, and the effect of the present invention may be reduced.

  Examples of the “enteric solvent” include fats and oils used in edible oils such as pectin, alginic acid, celluloses (for example, carboxymethylcellulose, cellulose acetate phthalate, etc.), (meth) acrylic acid copolymers, palm fats and oils, palm fats and oils, zein and the like. . Preferably, it is palm fats and oils at the point which shows the said effect. As a method of protecting with an intestinal solvent, a conventional means may be used, and specifically, a method of mixing with an ultraviolet-injury-preventing composition for ingestion and the like can be mentioned.

(Enteric coating)
In the present invention, the compound that coats the “UV damage preventing composition for ingestion” to protect it from gastric juice is referred to as an enteric coating agent. Whether or not the component obtained from the specific melon is already encapsulated in the intestinal solvent, and further contains an ultraviolet ray injury preventing composition for ingestion containing it, if necessary, encapsulated in a hard capsule, soft capsule, etc. The surface of these contents is preferably coated with an enteric coating agent by a conventional coating means such as spraying, dipping or vapor deposition. A method of spraying the surface of the contents is preferable in that it can be uniformly coated and can be kept at a low temperature. The combined use with an enteric coating has an effect of reliably reaching the intestinal ultraviolet injury preventing composition for oral intake without being affected by the conditions of the ingestor. Therefore, when no enteric coating is used, the protein activity of most UV-injured compositions for oral consumption can be degraded in the stomach depending on the condition of the intake, so that the enzyme activity is deactivated. As a result, the effect of the present invention may be reduced.

  Enteric coatings include celluloses such as ethyl cellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylcellulose, cellulose acetate phthalate, shellac, zein, lactoferrin, polyglycolactic acid, polylactic acid, lactic acid Examples include glycolic acid copolymers (polylactide-co-glycolide), methacrylic acid copolymers, aminoalkyl methacrylate polymers, etc. As food enteric coatings, shellac or zein is preferable, and natural proteins are particularly preferable. Zein in terms.

  Moreover, the thickness of the layer of the enteric coating agent when coated with the enteric coating agent is 0.1 μm to 50 μm, preferably 1 μm to 20 μm, and more preferably 1 μm to 10 μm. If the thickness of the layer is too thick, dissolution in the intestine may be delayed, and if it is too thin, it may dissolve in the stomach, or the enzyme activity in the intestine may be insufficient.

<Other ingredients>
In addition to the above-mentioned components, the ultraviolet ray injury preventing composition for oral ingestion of the present invention may be blended with other drugs and further components normally used in oral administration preparations depending on the purpose. For example, excipients, diluents, binders, disintegrants, sweeteners, tonics, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, solubilizers, buffers, lubricants, suspensions Examples thereof include an agent, a coloring agent, and a flavoring agent.

  Here, examples of the excipient include sugars such as lactose, glucose, lactose, purified white sugar, and glucose; polysaccharides such as pullulan and dextrin: sugar alcohols such as D-mannitol, sorbitol, xylitol, and erythritol; Examples include starches. Examples of the binder include hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, dextrin, pregelatinized starch and the like. Disintegrants include crystalline cellulose, carboxymethylcellulose, sodium carboxymethylcellulose, pregelatinized starch, wheat starch, corn starch and other starches, magnesium silicate, soft anhydrous silicic acid, synthetic aluminum silicate, calcium stearate, magnesium carbonate, actisol , Primogel, ExproTag, magnesium aluminate metasilicate, and the like. Lubricants include magnesium stearate, talc and the like, and suspending agents include tragacanth, gum arabic, xanthan gum, sodium alginate and the like. Examples of the sweetener include saccharin sodium and aspartame. Examples of flavoring agents include citrus flavors such as orange and lemon, menthol and peppermint oil. Examples of the colorant include natural pigments and synthetic pigments. These are particularly preferably selected from natural products.

<Dosage form>
Examples of preparations for oral administration (oral preparations) include tablets, pills, granules, capsules, powders, solutions, suspensions, syrups, etc., all of which are preferably used, but stable and simple. In particular, capsules and the like are preferable.

  In formulating, a pharmaceutically acceptable carrier can be mixed. For example, water, alcohol, edible oil, or the like can be used as the liquid carrier. As the solid carrier, amino acids such as lysine, polysaccharides such as cyclodextrin, organic acid salts such as magnesium stearate, cellulose derivatives such as hydroxylpropylcellulose, and the like can be used. Furthermore, various pharmaceutical additives can be blended.

<Processing Method for UV Injury Prevention Composition for Oral Ingestion>
The composition for preventing UV injury for oral intake of the present invention is produced by processing a component appropriately selected from the above components by any method. For example, a method of kneading in an aqueous medium and then wet granulation, a method in which the granule components are mechanically stirred together with an optional excipient, etc., a dry granulation method, a particle component is mechanically stirred, and a capsule There is a method of filling. A method in which the granular component is mechanically stirred and filled into a capsule is preferable in that the protein component of the composition for preventing UV injury for oral intake can be stably secured.

  The obtained granules can be ingested as they are, but may be encapsulated in a capsule or the like for ease of ingestion. When not encapsulated in a capsule or the like, it is preferable to take it mixed with yoghurt, dietary fiber and oils and fats such as mayonnaise and butter from the viewpoint of preventing decomposition by gastric juice. Moreover, there is no restriction | limiting in particular as a capsule, If it is used for oral intake, it can select arbitrarily. Specifically, for example, hard capsules, soft capsules, microcapsules, etc., preferably soft capsules made of gelatin, more preferably capsules made of porcine gelatin. Furthermore, the capsule surface may be coated with saccharides, polymers, etc. in consideration of the feeling of medication and drug stability. Furthermore, as described above, coating with an enteric coating agent synergistically increases the effects of the present invention.

<Intake and use>
The amount of oral intake of the composition for preventing UV injury for oral intake is not particularly limited, but is preferably 20 mg / day to 1 g / day, more preferably 50 mg / day to 800 mg / day, and particularly preferably 200 mg / day to 500 mg / day. . It is not necessary to take the daily oral intake at a time, and it may be taken in several divided doses. From the point of being easy to take at a time, 10 mg / dose to 0.5 g / dose is preferred, 25 mg / dose to 400 mg / dose is more preferred, and 100 mg / dose to 250 mg / dose is particularly preferred. The ultraviolet ray injury preventing composition for oral intake of the present invention contained per oral preparation such as a capsule is preferably 10 mg / oral preparation to 0.5 g / oral preparation, more preferably 25 mg / oral preparation to 400 mg / oral preparation. 100 mg / oral to 250 mg / oral is particularly preferable.

In addition, the oral intake of each component in the composition for preventing UV injury for oral intake is not particularly limited, but in terms of solid content,
The component obtained from the specific melon is preferably 0.1 mg to 100 mg / day,
1 mg to 20 mg / day is more preferable,
The red wine component is preferably 0 mg to 350 mg / day,
10 mg to 200 mg / day is more preferable,
The component obtained from the pine bark is preferably 0 mg to 200 mg / day,
10 mg to 120 mg / day is more preferable,
The above vitamin C is preferably 0 mg to 350 mg / day,
1 mg to 200 mg / day is more preferable.

  The amount of each component contained per oral preparation such as a capsule is preferably a half (1/2) of each (more) preferable range of the daily intake.

  The intake period is preferably 14 days or longer, more preferably 30 days or longer, and particularly preferably 90 days or longer. Moreover, continuous intake is preferable. If the amount is too small, the above effect may not be exhibited. If the amount is too large, a further effect cannot be expected, which may be useless.

  The composition for preventing UV injury for oral intake and the oral preparation of the present invention are not only used as a drug for treatment and prevention of UV damage, but also skin care products such as whitening cosmetics and skin care cosmetics, and skin care products for oral intake. , Foods and drinks, food ingredients and other ingredients are also suitably blended and used.

<Action>
The action / principle of suppressing or preventing UV damage by ingesting the UV damage preventing composition for oral consumption according to the present invention is not clear, and the present invention is not limited to the scope of such action / principle. The following are possible. That is, in the composition for preventing UV injury for oral ingestion of the present invention, the components obtained from the fruit of the variety of Cucumis melo are mainly composed of SOD (superoxide desmutase), catalase, etc. Active oxygen generated by foods such as fat and food-derived chemical compounds in the intestine is converted to water through hydrogen peroxide. In addition, it is generally known that a living body exposed to oxygen stress has an increased ability to react with active oxygen, and one or more reactants of active oxygen → hydrogen peroxide → water generated in the intestine are high in the living body. It is thought that the enhancement of the oxygen stress function was induced. It is presumed that the components obtained from the fruit of the variety of Cucumis melo detoxify the active oxygen directly, and that this reaction process has exerted a UV damage prevention effect by some mechanism of action.

  Further, vitamin C and / or a red wine component containing a polyphenol component derived from grape skin or seed and / or a component obtained from pine bark such as hydroxyflavan or a derivative thereof or an oligomer thereof. As a result, the effect of the present invention appears more prominently by simultaneously suppressing the occurrence of chain oxidation of peroxidation reactions of nucleic acids, proteins and lipids induced by active oxygen. This is thought to be due to the synergistic increase in suppression of the series of reactions caused by.

  EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples and comparative examples. However, the present invention is not limited to these examples unless it exceeds the gist.

<Preparation of composition for preventing UV injury for oral consumption>
(Preparation of ingredients obtained from the fruit (special melon) of Kukamisu Melo varieties)
100 parts by weight of the above-mentioned Kukamis-Mello variant pulp was ground with 100 parts by weight of deionized water for 0.5 hour. At this time, it grind | pulverized on the conditions of zero ice temperature, pH 6.5-7.5, and normal pressure using the blender. After pulverization, only the supernatant (water-soluble fraction) was collected and concentrated and dried using a freeze dryer to obtain 20 parts by mass of a powdery volume average particle size 200 μm composition. 80 parts by mass of palm oil / fat as an intestinal solvent was mixed with the resulting composition and included in palm oil / fat.

  The main components of the composition obtained here are shown in Table 1, but the present invention is not limited to this. Details of the components contained in the composition obtained from the specific melon of the present invention and the true active ingredients Is unknown.

(Processing of UV injury prevention composition for ingestion)
Ingredients obtained from the fruit (special melon) of Kukamisu melo varieties (extramel (registered trademark), from Sedaherb Japan), which is the same as that prepared in the above-mentioned “Preparation of Ingredients from Specific Melon” Obtained) 70 parts by weight and 100 parts by weight of vitamin C (DSM Nutritional Products (UK) Limited Dalry), red wine ingredients (trade name: Provinols (registered trademark), 100 parts by Sedaherb Japan), hydroxy Ingredients obtained from pine bark such as flavan or derivatives thereof or oligomers thereof (trade name: POLY-PINE (registered trademark), obtained from Sedaherb Japan) 60 parts by weight, cellulose 110 parts by weight, rocking mixer It mixed until it became the state of uniform dispersion using the V type mixer.

  Thereafter, 220 mg of the above mixture is encapsulated in a capsule made of porcine gelatin, and zein (manufactured by Ogawa Fragrance Co., Ltd.) is sprayed as an enteric coating agent to form a 5 to 10 μm layer of the enteric coating agent. The composition was dried to obtain a composition for preventing UV injury for oral consumption.

Example 1
To 7 healthy women aged 35 to 45 (subjects No. 1 to No. 7), 2 capsules for preventing UV injury for oral intake obtained above (cellulose, capsule and enteric coating were excluded) (Equivalent to 330 mg of active ingredient) was ingested once a day for 28 days, and then the back was irradiated with ultraviolet rays using an ultraviolet irradiation apparatus USHIO Optical Module. The ultraviolet irradiation at this time is provided with six circular ranges each having a diameter of about 1 cm in the intake [1] portion and the intake [2] portion of FIG. Ultraviolet irradiation was performed with a relative ultraviolet irradiation amount. The irradiation ultraviolet irradiation wavelength includes both a wavelength range of UVA having a relatively long wavelength and UVB having a relatively short wavelength. Details are shown below. Here, the unit of the numerical values (relative ultraviolet irradiation amount) shown in Table 2 is 5.83 [μW / (cm ² / hr)].

表２中、肌のタイプ「色白」は被験者Ｎｏ．１、４、５、７であり、「普通−色黒」は被験者Ｎｏ．２、３、６である。

In Table 2, the skin type “white” is the subject No. 1, 4, 5, and 7, "Normal-color black" is the subject No. 2, 3, and 6.

  The degree of erythema (redness) after 1 day of irradiation and the degree of melanin deposition after 7 days of irradiation were measured using visual observation and a megsometer, respectively. In addition to the 28 days prior to irradiation, until 7 days after irradiation, 330 mg of the active ingredient for ultraviolet injury prevention composition for oral consumption obtained above, that is, 2 capsules, was taken once a day in the same amount as before ultraviolet irradiation. Continued.

Comparative Example 1
Evaluation was performed by irradiating with ultraviolet rays in the same manner as in Example 1 except that the composition for preventing oral injury of ultraviolet rays was not taken. The ultraviolet irradiation at this time was similarly performed at the doses shown in Table 2 in the non-intake [1] and non-intake [2] portions of FIG.

Example 2
Except that the capsule was not coated with an enteric coating agent, a composition for preventing UV injury for oral consumption was prepared in the same manner as in Example 1, and the same evaluation as in Example 1 was carried out, but only a simple visual evaluation was performed.

Example 3
In the same manner as in Example 1, a component obtained from a variety of Cucamis melo varieties (specific melon) was prepared, and only that was used as an enteric coating in the same manner as in Example 1 to produce zein (manufactured by Ogawa Fragrance Co., Ltd.). Was used to prepare a composition for preventing UV injury for oral ingestion, and the same evaluation as in Example 1 was carried out, but a simple evaluation only for visual judgment was performed.

Comparative Example 2
Evaluation was performed by irradiating ultraviolet rays in the same manner as in Example 1 except that 330 mg of vitamin C alone was taken instead of taking the ultraviolet ray injury preventing composition for oral intake.

Comparative Example 3
Instead of ingesting the UV injury prevention composition for oral consumption, the product name: Provinols (registered trademark) (obtained from Sedaherb Japan) was irradiated in the same manner as in Example 1 except that 330 mg was ingested. Evaluation was performed.

Comparative Example 4
Instead of ingesting the UV injury prevention composition for oral consumption, UV light was applied in the same manner as in Example 1, except that only 330 mg of the trade name: POLY-PINE (registered trademark) (obtained from Sedaherb Japan) was ingested. Irradiated and evaluated.

Hereinafter, the evaluation result of the composition for preventing UV injury for oral intake prepared in Example 1 is shown together with the evaluation result of Comparative Example 1.
<Evaluation 1: Visual determination of erythema (redness) and melanin deposition>
After 1 day of ultraviolet irradiation, the occurrence of erythema (redness) was observed, and 7 days later, the presence or absence of melanin deposition was divided into the following four stages, and each part was visually judged. The results are shown in Table 3.
-: No erythema (redness) or melanin deposition ±: Cannot be judged whether erythema (redness) or melanin deposition +: Erythema (redness) or melanin deposition ++: Remarkably erythema (redness) or melanin deposition Yes

<Evaluation 2: Measurement of erythema (redness) and melanin deposition by meggameter>
The occurrence of erythema (redness) 1 day after UV irradiation was measured using a megsometer MX18 (Courage + Khazaka Elctronic Gmbh). For the occurrence of erythema (redness), the reflected light intensity (erythma value) of each part at a wavelength of 660 nm was used for evaluation. As the reference, the reflected light intensity of each part at a wavelength of 880 nm was used. The results are shown in FIGS. Here, the vertical axis of FIG. 3 is the “Δ erythma value”, which is a difference value from the minimum value obtained from the three-point moving average curve of FIG. The unit of the horizontal axis (relative ultraviolet irradiation amount) in FIGS. 2 and 3 is 5.83 [μW / (cm ² / hr)].

With the analysis method shown in FIG. 4, the results of the occurrence of erythema (redness) shown in FIG. 2, FIG. 3 and Table 3 were considered. The consideration results are shown in Table 4, Table 5, and FIG. here,
The y-axis shown in FIG. 4 is the Δ erythma value or the visual judgment result divided into four stages,
b is the ultraviolet ray irradiation amount in which the visual determination result of Comparative Example 1 changes from − to ±, or the value of the x intercept when linearly approximating the Δ erythma value obtained from the megsometer,
d is the UV irradiation amount at which the visual judgment result of Example 1 changes from − to ±, or the value of the x intercept when linearly approximating the Δ erythma value obtained from the megsometer,
b20 is the irradiation amount of the relative ultraviolet irradiation amount when the Δ-erythma value of Comparative Example 1 is increased by 20,
d20 is the irradiation amount of the relative ultraviolet irradiation amount when the Δ-erythma value of Example 1 is increased by 20,
MED is the lowest UV irradiation amount that can confirm erythema (redness) visually when the visual judgment of Comparative Example 1 changes from ± to +, that is,
HED is the amount of UV irradiation when the visual judgment in Comparative Example 1 changes from + to ++,
ΔMED is (the lowest UV irradiation amount that can visually confirm erythema (redness) in Example 1)-(the lowest UV radiation amount that can visually confirm erythema (redness) in Comparative Example 1),
ΔHED is (the amount of ultraviolet irradiation when the visual judgment of erythema (redness) in Example 1 changes from + to ++) − (when the visual judgment of erythema (redness) in Comparative Example 1 changes from + to ++. UV irradiation)
Respectively, y = c (x−d) is an approximate expression when the result of the elliptic value of Example 1 is linearly approximated, and y = c (x−d) is an approximate expression when the result of the elliptic value of Comparative Example 1 is linearly approximated. It was set as a (xb).
ΔMMD is (the lowest UV irradiation amount at which melanin deposition can be confirmed visually in Example 1)-(the lowest UV irradiation amount at which melanin deposition can be confirmed visually in Comparative Example 1),
ΔHMD is (the amount of UV irradiation when the visual judgment of melanin deposition in Example 1 changes from + to ++) − (the amount of UV irradiation when the visual judgment of melanin deposition in Comparative Example 1 changes from + to ++)

  Further, in the visual judgment, when the values of “ΔMED” and “ΔHED” are 0 or more, it is considered effective, and when “ΔHED” is larger than 0, it is markedly effective. In the determination by the megsometer, there is dependency on the amount of ultraviolet irradiation, and when the values of “db” and “d20-b20” are 0 or more, it is considered effective, and “db” and “d20-b20”. When both values were greater than 0, the results were markedly effective. In addition, the overall judgment is effective when the effect is recognized by either the visual judgment or the judgment result by the meggameter. If both the visual judgment and the judgment by the meggameter are both effective, the overall judgment is markedly effective. .

The analysis results of erythema (redness) are shown in Table 4 below. The unit of the numerical values (relative ultraviolet irradiation amount) shown in Table 4 is 5.83 [μW / (cm ² / hr)].

The analysis results of melanin deposition are shown in Table 5 below. The unit of the numerical value (relative ultraviolet irradiation amount) shown in Table 5 is 5.83 [μW / (cm ² / hr)]. In Table 5, “SD” indicates a standard deviation.

  From Table 4, it was found that the measurement result of erythema (redness) by the meggameter showed the same tendency as the visual judgment. As a result of these, all 7 people have an effect in the comprehensive judgment, and by taking the ultraviolet ray injury preventing composition for oral intake of the present invention for 28 days, the effect of preventing the injury induced by ultraviolet irradiation is seen. I understood. In addition, the subject No. in which a particularly remarkable effect was observed. 1, no. 6 and no. In No. 7, the visual determination and the determination result by the meggameter were quantitatively close.

  Moreover, what averaged the result of all the test subjects using the analysis method shown in FIG. 4 was shown in FIG. As can be seen from FIG. 3 and FIG. 5, it can be seen that when the composition for preventing UV injury for oral consumption of the present invention is ingested, the effect of reducing the change in the erythema value, that is, the effect of preventing injury due to UV irradiation. It was.

  Regarding the measurement result of melanin deposition, an effect was recognized in 6 out of 7 people by visual judgment, and melanin deposition induced by ultraviolet irradiation by ingesting the UV injury prevention composition for oral consumption of the present invention for 28 days. It was found that the effect of preventing the occurrence was observed (Table 5).

  In the case of the UV injury-preventing composition for ingestion of Example 2 that is included in palm oil or fat as an intestinal solvent but is not coated with an enteric coating agent, it has the effect of preventing damage induced by UV irradiation. Although it was inferior to that of Example 1, it was still effective. By comparing Example 1 and Example 2, it was confirmed that the coating with an enteric coating was effective.

  The composition for preventing UV injury of orally ingested Example 3 in which only the components obtained from the fruit of a variety of Cucumis melo (specific melon) were included with palm oil as an intestinal solvent and coated with zein as an enteric coating agent, Although the effect of preventing injury induced by ultraviolet irradiation was slightly inferior to that of Example 1, it still showed a remarkable effect.

  Moreover, in Example 3, what was not coat | covered with zein as an enteric coating agent also had the effect which prevents the injury induced by ultraviolet irradiation. However, although it is considered that decomposition occurred in the stomach as compared with the ultraviolet ray injury preventing composition for oral intake of Example 3, the effect of preventing injury induced by ultraviolet irradiation was inferior.

  Ingredients obtained from specific melon, vitamin C, red wine ingredient containing grape skin or seed-derived polyphenol ingredients, and / or ingredients obtained from pine bark such as hydroxyflavan or derivatives thereof or oligomers thereof It was found that the effect was synergistically improved by combining.

  In addition, the composition of the present invention is not the composition for preventing UV injury for oral intake, but only vitamin C (Comparative Example 2), only the red wine component (Comparative Example 3), and only the component obtained from pine bark (Comparative Example 4). Even when the amount was ingested, the result was similar to that of Comparative Example 1, and no significant effect as in the Example was observed.

Example 4
Further, for four healthy 35- to 45-year-old women (subjects No. 8 to No. 11), the same composition for oral injury as in Example 1 was ingested in the same manner as in Example 1, Similarly, ultraviolet rays were irradiated for evaluation.

Comparative Example 5
Evaluation was performed by irradiating with ultraviolet rays in the same manner as in Example 4 except that the composition for preventing oral injury of ultraviolet rays was not ingested. The ultraviolet irradiation at this time was performed at the doses shown in Table 2 in the same manner as in Example 1 in the non-intake [1] and non-intake [2] portions of FIG.

<Evaluation 3: Visual determination of erythema (redness) and melanin deposition>
The appearance of erythema (redness) occurred 1 day after UV irradiation, and the presence or absence of melanin deposition after 7 days, was visually determined for each site in the following four stages. The evaluation results of Example 4 and Comparative Example 5 are shown together in Table 6.
-: No erythema (redness) or melanin deposition ±: Cannot be judged whether erythema (redness) or melanin deposition +: Erythema (redness) or melanin deposition ++: Remarkably erythema (redness) or melanin deposition Yes

<Evaluation 4: Measurement of erythema (redness) by meggameter>
The occurrence of erythema (redness) 1 day after the ultraviolet irradiation was measured using a meggameter MX18 (Courage + Khazaka Elctronic Gmbh). For the occurrence of erythema (redness), the reflected light intensity (erythma value) of each part at a wavelength of 660 nm was used for evaluation. As the reference, the reflected light intensity of each part at a wavelength of 880 nm was used. The results are shown in FIGS. 6 and 7, the unit of the horizontal axis (relative irradiation ultraviolet ray amount) (MED) is 1 [MED] = 5.83 [μW / (cm ² / hr)].

<Evaluation 5: Confirmation of erythema (redness) prevention effect by ultraviolet irradiation>
Furthermore, in order to confirm the effect of the present invention, the following evaluation was performed. In the visual judgment obtained in the above-mentioned evaluations 1 and 3, the amount of ultraviolet rays (hereinafter referred to as “erythema production detection dose”) in two stages below the amount of ultraviolet rays that gives (±) in the visual judgment of erythema (redness) one day after ultraviolet irradiation. For each subject. Next, based on the results of Evaluation 2 and Evaluation 4, the average value of the erythema value from the amount of ultraviolet rays 0 to the detected dose of erythema was determined for each subject. The erisma value is measured at two or more places per subject, and the erythma value at one place is an average value of five measurements. The results are shown in Table 7.

  In Table 7, “SD” indicates standard deviation, and “P value” (P-value) indicates that the null hypothesis is that there is no difference in the average value of the erythema value between non-intake and intake. This is the significance probability. Normally, if the P value is 0.05 or less, the null hypothesis is rejected, and both distributions are considered to have a significant difference, and if it is 0.01 or less, it is assumed that there is a very significant difference.

  As is clear from the results of Table 7, when the composition for preventing UV injury of oral intake of the present invention was ingested (Examples 1 and 4), compared with the case of non-ingestion (Comparative Examples 1 and 5), The average value of the erythema value in Evaluation 5 was small in almost all subjects. Further, since the P value was 0.0028, it was found that the null hypothesis “there is no difference in the average value of the erythema value between non-intake and intake” is only correct with a probability of 0.0028. In other words, the null hypothesis was rejected and it was found that there was a significant difference between the two distributions. In other words, it was found that when the composition for preventing UV injury for oral intake of the present invention was ingested, the average value of the erythema value was small with a significant difference compared to the case of non-ingestion.

  That is, even when the amount of ultraviolet rays that does not lead to the generation of erythema (redness) due to ultraviolet irradiation (irradiation detection dose from 0 to the amount of ultraviolet rays) is irradiated, the composition for preventing UV injury of the present invention is ingested. In that case, compared to the case of non-ingestion, the erythema value of the irradiated site was significantly reduced, and the redness (erythma value) of the skin not irradiated with the erythema production detection dose was reduced. As a result.

  From the above, it was found that by ingesting the ultraviolet ray injury preventing composition for oral consumption of the present invention, the effects of suppressing the occurrence of damage induced by ultraviolet irradiation, such as erythema (redness) and melanin deposition, were observed. (Examples 1 to 3, Comparative Examples 1 to 4, Evaluations 1 and 2). Furthermore, even when the damage caused by UV irradiation does not reach such a level that it can be visually observed, the erythema value of the site irradiated with such UV irradiation dose is significantly lower after ingestion than before ingestion. That is, the whitening effect was recognized after ingestion (Example 4, Comparative Example 4, Evaluation 3 to 5).

  The composition for preventing UV injury of oral intake of the present invention has an effect of promoting the function of anti-active oxygen inherent in the living body, and is widely used for the prevention of aging and diseases derived from active oxygen and oxidation. is there. For example, diseases of the circulatory system, respiratory system, cranial nervous system, digestive system, blood system, endocrine system, urinary system, supporting tissue system, genital system, etc. and prevention of skin spots, wrinkles, burns and senile plaques, moisturizing It is widely used for the prevention of atopy and allergy suppression by sex, resistance to stress, agricultural chemicals, organic solvents and synthetic compounds.

  This application is based on Japanese Patent Application No. 2007-208434 filed on August 9, 2007, the entire contents of which are hereby incorporated by reference herein as disclosure of the specification of the present invention. It is taken in.

Claims (6)

Ingested by humans to prevent melanin deposition due to ultraviolet rays including the UVA wavelength range, and the components obtained from the fruit of the variety of Cucumis melo are included with palm oil; grape pulp, polyphenols contained in red wine obtained by fermenting the peel or seeds; component obtained from pine bark; and; melanosis inhibiting composition according to ultraviolet for oral ingestion containing vitamin C the surface of the capsule which is sealed A capsule for preventing melanin deposition by ultraviolet rays for oral consumption, characterized by being coated with zein to a thickness of 1 μm to 20 μm. The pine components obtained from the bark is a pine bark is a component obtained by hot water extraction claim 1 melanosis prevention capsules by UV for oral ingestion according. The capsule for preventing melanin deposition by ultraviolet rays for oral consumption according to claim 1 or 2 , wherein the component obtained from the pine bark is hydroxyflavan or a derivative thereof or an oligomer thereof. The components obtained from the fruit of Kyukamisu Melo variants, for people to prevent UV damage, claims 1 to 3 were prepared so as to be orally ingested in the range of 0.1mg~100mg day The capsule for preventing melanin deposition by ultraviolet rays for ingestion according to any one of the preceding claims. The capsule for preventing melanin deposition by ultraviolet rays for ingestion according to any one of claims 1 to 4 , wherein a human is a daily equivalent of 0.1 mg to a component converted from a fruit of a variety of Cucumis melo A method of whitening the skin, which is taken orally in the range of 100 mg. The method of whitening the skin according to claim 5 , wherein a human continuously ingests the capsule for preventing melanin deposition by ultraviolet rays for ingestion according to any one of claims 1 to 4 for 14 days or more.

Images